2026-04-17T12:06:15Zhttps://recercat.cat/oai/requestoai:recercat.cat:10230/450632025-12-19T22:58:43Zcom_2072_6col_2072_452952
Data on the endogenous conversion of tyrosol into hydroxytyrosol in humans
Boronat Rigol, Anna, 1990-
Mateus Rodriguez, Julian Andrés
Soldevila-Domenech, Natalia
Guerra Albà, Mercè
Rodríguez-Morató, Jose, 1987-
Varon, Carlota
Muñoz, Daniel
Barbosa, Francina
Morales, Juan Carlos
Gaedigk, Andreas
Langohr, Klaus
Covas Planells, Maria Isabel
Pérez Mañá, Clara
Fitó Colomer, Montserrat
Tyndale, Rachel F.
Torre Fornell, Rafael de la
CYP2A6
CYP2D6
Cardiovascular risk
Endogenous conversion
Hydroxytyrosol
Tyrosol
Here we present new and original data on the endogenous conversion of tyrosol (Tyr) into hydroxytyrosol (OHTyr) in humans and its effects on the cardiovascular system. A randomized, crossover, controlled clinical trial was performed with individuals at cardiovascular risk (n = 33). They received white wine (WW) (females 1, males 2 standard drinks/day), WW plus Tyr capsules (WW + Tyr) (25mg Tyr capsule, one per WW drink), and water (control) ad libitum. Intervention periods were of 4 weeks preceded by three-week wash-out periods. We assessed the conversion of Tyr to OHTyr, its interaction with a polygenic activity score (PAS) from CYP2A6 and CYP2D6 genotypes, and the effects on cardiovascular risk markers. For further details and experimental findings please refer to the article "Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial"
2020-07-03T06:46:40Z
2020-07-03T06:46:40Z
2019
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Data Brief. 2019; 27:104787
© 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
Elsevier